Author + information
- Lukasz Koltowski,
- Janusz Kochman,
- Radoslaw Parma,
- Anorzej Ochala,
- Zenon Huczek,
- Adam Witkowski,
- Piotr Scislo,
- Marek Grygier,
- Maciej Lesiak,
- Eberhard Grube and
- Marian Zembala
Background: The aim of this study was to evaluate the outcomes of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BiAV) stenosis using a mechanically expanded Lotus™ device. The BiAV has been excluded from landmark clinical trials and is considered as relative contraindication to TAVI. The prior experience with first-generation devices has shown disappointing device success rates resulting mainly from increased prevalence of aortic regurgitation (AR) that exceeded those observed in tricuspid stenosis.
Methods: We collected baseline, in-hospital and 30-day follow-up data from the POL-TAVI database, which is an obligatory registry of all patients undergoing TAVI in Poland. The study group comprised 29 patients who underwent TAVI with Lotus™ valve.
Results: The mean age was 73.5 years and the mean EuroSCORE 2 was 4.35 ± 2.56. MDCT analysis revealed Type 1 BiAV in 75% of patients. The mean gradient decreased from 60.1 +/- 18.3 mm Hg to 15 +/- 6.4 mm Hg, the AVA increased from 0.6 +/- 0.19 cm2 to 1.7 +/- 0.21 cm2. No intraprocedural death was observed. There was no severe AR and the rate of moderate AR equaled 8% (n=2). Device success was achieved in 83% and the 30-day safety endpoint was 17%.
Conclusions: The TAVI in selected BAV patients using the Lotus™ is feasible and characterized by encouraging valve performance and clinical outcomes.
Poster Contributions Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Interventional Cardiology: TAVR 3
Abstract Category: 17. Interventional Cardiology: Aortic Valve Disease
Presentation Number: 1243-169
- 2017 American College of Cardiology Foundation